✦ LIBER ✦

532 Treatment with PEG-interferon and ribavirin for chronic hepatitis C does not decrease neutrophil and monocyte activity

✍ Scribed by A. Giorgini; F. Capsoni; A. Lleo; C. Selmi; A.M. Ongari; A. Benetti; B. Ferrari; P. Invernizzi; M. Podda; M. Zuin

Book ID: 117374809
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 130 KB
Volume: 44
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(06)80532-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment with PEG-interferon and Ribavi

Treatment with PEG-interferon and Ribavirin for Chronic Hepatitis C Increases Neutrophil and Monocyte Chemotaxis

✍ Giorgini, Alessia; Capsoni, Franco; Podda, Mauro; Lleó, Ana; Battezzati, Pier Ma 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 237 KB

COMBINATION TREATMENT WITH INTERFERON AN

COMBINATION TREATMENT WITH INTERFERON AND RIBAVIRIN FOR CHRONIC HEPATITIS C

✍ Davis, Gary L. 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 895 KB

Interferon and ribavirin treatment for c

Interferon and ribavirin treatment for chronic hepatitis C may activate celiac disease

✍ Luigi E Adinolfi; Emanuele Durante Mangoni; Augusto Andreana 📂 Article 📅 2001 🏛 Nature Publishing Group 🌐 English ⚖ 49 KB

Hepatic steatosis in chronic hepatitis C

Hepatic steatosis in chronic hepatitis C: impact on response to anti-viral treatment with peg-interferon and ribavirin

✍ M. GUIDI; P. MURATORI; A. GRANITO; L. MURATORI; G. PAPPAS; M. LENZI; F. B. BIANC 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

Retinopathy associated with pegylated in

Retinopathy associated with pegylated interferon and ribavirin treatment for chronic hepatitis C

✍ Shelly Adams; Mark Ostermeier 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 995 KB

Rapid onset of ulcerative colitis after

Rapid onset of ulcerative colitis after treatment with PEG-interferon plus ribavirin for chronic hepatitis C

✍ Antonio Tursi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 53 KB

infliximab. In contrast, similar psoriasiform lesions are reported to have been induced by infliximab in a few patients with inflammatory bowel diseases. [3][4][5][6][7] Such an undesired, dermatologically adverse effect is considered a delayed hypersensitivity reaction that commonly occurs during v